AIMS: This study aimed to characterise the status of viral infection in patients with HTLV-1 uveitis (HU) by quantifying the circulating HTLV-1 infected cells in the peripheral blood. METHODS: Genomic DNA samples of peripheral blood mononuclear cells (PBMC) were obtained from 25 patients with HU, 14 patients with tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM), and 21 asymptomatic carriers of HTLV-1. Quantitative polymerase chain reaction (PCR) of the gag region of HTLV-1 provirus DNA was performed on these DNA samples. To confirm the PCR, genomic Southern blot hybridisation was performed to identify integrated HTLV-1 provirus. This procedure detected a few percent of HTLV-1 infected cells in the PBMC. RESULTS: Most of the HU patients had a significantly increased number of circulating HTLV-1 infected cells (mean (SD) 3.84% (4.45%) of the PBMC), whereas the percentage of infected cells in most asymptomatic carriers was less than 1% (0.54% (1.11%)). Most of the TSP/HAM patients also had a relatively high percentage (11.63% (7.67%)). The differences among these three groups were highly significant by the Mann-Whitney U test. CONCLUSION: The results suggested that the increase in the number of HTLV-1 infected cells is one base for the development of inflammatory HU lesions, as it is for TSP/HAM.
AIMS: This study aimed to characterise the status of viral infection in patients with HTLV-1 uveitis (HU) by quantifying the circulating HTLV-1 infected cells in the peripheral blood. METHODS: Genomic DNA samples of peripheral blood mononuclear cells (PBMC) were obtained from 25 patients with HU, 14 patients with tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM), and 21 asymptomatic carriers of HTLV-1. Quantitative polymerase chain reaction (PCR) of the gag region of HTLV-1 provirus DNA was performed on these DNA samples. To confirm the PCR, genomic Southern blot hybridisation was performed to identify integrated HTLV-1 provirus. This procedure detected a few percent of HTLV-1 infected cells in the PBMC. RESULTS: Most of the HU patients had a significantly increased number of circulating HTLV-1 infected cells (mean (SD) 3.84% (4.45%) of the PBMC), whereas the percentage of infected cells in most asymptomatic carriers was less than 1% (0.54% (1.11%)). Most of the TSP/HAM patients also had a relatively high percentage (11.63% (7.67%)). The differences among these three groups were highly significant by the Mann-Whitney U test. CONCLUSION: The results suggested that the increase in the number of HTLV-1 infected cells is one base for the development of inflammatory HU lesions, as it is for TSP/HAM.
Authors: K Nagasato; T Nakamura; K Ohishi; K Shibayama; M Motomura; K Ichinose; M Tsujihata; S Nagataki Journal: J Neuroimmunol Date: 1991-05 Impact factor: 3.478
Authors: M Mochizuki; T Watanabe; K Yamaguchi; K Yoshimura; S Nakashima; M Shirao; S Araki; K Takatsuki; S Mori; N Miyata Journal: Am J Ophthalmol Date: 1992-08-15 Impact factor: 5.258
Authors: S Ijichi; N Eiraku; M Osame; S Izumo; R Kubota; I Maruyama; M Matsumoto; T Niimura; S Sonoda Journal: J Neuroimmunol Date: 1989-12 Impact factor: 3.478
Authors: Y Iwakura; M Tosu; E Yoshida; M Takiguchi; K Sato; I Kitajima; K Nishioka; K Yamamoto; T Takeda; M Hatanaka Journal: Science Date: 1991-08-30 Impact factor: 47.728
Authors: M Mochizuki; T Watanabe; K Yamaguchi; K Takatsuki; K Yoshimura; M Shirao; S Nakashima; S Mori; S Araki; N Miyata Journal: Jpn J Cancer Res Date: 1992-03
Authors: S J Kim; J H Kehrl; J Burton; C L Tendler; K T Jeang; D Danielpour; C Thevenin; K Y Kim; M B Sporn; A B Roberts Journal: J Exp Med Date: 1990-07-01 Impact factor: 14.307
Authors: Ana Karina Ferraz-Chaoui; Ajax Mercês Atta; Maria Luiza Sousa Atta; Bernardo Galvão-Castro; Mittermayer B Santiago Journal: Rheumatol Int Date: 2009-07-29 Impact factor: 2.631
Authors: K Nakatani; K Imai; M Shigeno; H Sato; M Tezuka; T Okawa; N Mitsuiki; T Isoda; D Tomizawa; M Takagi; M Nagasawa; M Kajiwara; M Yamamoto; A Arai; O Miura; C Kamae; N Nakagawa; K Honma; S Nonoyama; S Mizutani; T Morio Journal: Bone Marrow Transplant Date: 2014-06-30 Impact factor: 5.483